CTSO: הכנסות ממכירות החברה CytoSorbents Corporation

Slow approval in the US is constraining the global pricing power of Cytosorbents (CTSO), yet the company's operating revenue dynamics demonstrate resilience. The value of 0.04 represents the current level of the indicator. Stability is ensured by the integration of adsorbers into intensive care infrastructure and diversification through the application of technologies in cardiac surgery and poisoning therapy, which mitigates industry risks.

Cytosorbents occupies a strategic niche in the production of extracorporeal blood purification systems for intensive care. By analyzing the company's aggregate sales volume, an investor can track the dynamics of daily cash inflows from the sale of disposable cartridges. This metric captures the deviation of actual revenue from projected values, revealing the operational stability of the business. Regular demand for consumables ensures high margins and minimizes the risk of capital freeze.